Matthew Stanton
Stock Analyst at Jefferies
(0.02)
# 4,769
Out of 5,242 analysts
8
Total ratings
20%
Success rate
-41.58%
Average return
Main Sectors:
Stocks Rated by Matthew Stanton
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AZTA Azenta | Maintains: Buy | $42 → $40 | $19.54 | +104.71% | 3 | Feb 4, 2026 | |
| RGEN Repligen | Maintains: Hold | $145 → $135 | $113.37 | +19.08% | 1 | Sep 12, 2025 | |
| CYRX Cryoport | Downgrades: Hold | $20 → $8 | $14.22 | -43.74% | 2 | Aug 7, 2024 | |
| LAB Standard BioTools | Initiates: Buy | $3.25 | $1.04 | +212.50% | 1 | Apr 4, 2024 | |
| BLFS BioLife Solutions | Initiates: Buy | $22 | $24.74 | -11.08% | 1 | Apr 4, 2024 |
Azenta
Feb 4, 2026
Maintains: Buy
Price Target: $42 → $40
Current: $19.54
Upside: +104.71%
Repligen
Sep 12, 2025
Maintains: Hold
Price Target: $145 → $135
Current: $113.37
Upside: +19.08%
Cryoport
Aug 7, 2024
Downgrades: Hold
Price Target: $20 → $8
Current: $14.22
Upside: -43.74%
Standard BioTools
Apr 4, 2024
Initiates: Buy
Price Target: $3.25
Current: $1.04
Upside: +212.50%
BioLife Solutions
Apr 4, 2024
Initiates: Buy
Price Target: $22
Current: $24.74
Upside: -11.08%